NOVELIX PHARMACEUTICALS LIMITED

Healthcare · Healthcare Services

BSE: 536565 BSE: 590093
₹70.00
▼ -0.05 (-0.07%)
Sept. 30, 2026 · BSE · bse_bhavcopy
Quality
65/100
Moderate
Valuation
49/100
Fairly Valued
Momentum
48/100
Neutral

QVM read Mixed signals Quality Moderate, Valuation Fairly Valued, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹167 Cr
PE (TTM)
37.4
Industry median 50.2 (44 companies)
Price to Book
3.6
PEG (TTM)
0.2
Institutions holding %
Data unavailable.
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
Data unavailable.
Relative return vs Sector, qtr %
Data unavailable.
Free Cash Flow
₹-26 Cr
as of March 31, 2026
Industry median ₹1 Cr (75 companies)
EPS Growth (YoY)
444.44%
as of June 30, 2026
Industry median 13.27% (57 companies)
Net Profit Growth (TTM)
350.00%
as of June 30, 2026
Industry median 7.21% (57 companies)
Operating Revenue Growth (TTM)
179.92%
as of June 30, 2026
Industry median 12.82% (57 companies)
Profit Growth (YoY)
398.36%
as of March 31, 2026
Industry median 8.53% (57 companies)
Revenue Growth (YoY)
65.16%
as of June 30, 2026
Industry median 18.84% (52 companies)
Current Ratio
2.14
as of March 31, 2026
Industry median 2.06 (74 companies)
Debt to Equity
0.09
as of March 31, 2026
Industry median 0.11 (62 companies)
Interest Coverage
38.69
as of June 30, 2026
Industry median 7.94 (57 companies)
Net Margin
3.62%
as of March 31, 2026
Industry median 9.88% (61 companies)
Operating Margin (EBIT)
3.33%
as of June 30, 2026
Industry median 17.21% (61 companies)
Operating Margin (TTM)
3.04%
as of June 30, 2026
Industry median 16.20% (59 companies)
Return on Assets
2.77%
as of March 31, 2026
Industry median 5.40% (58 companies)
Return on Capital Employed
6.70%
as of March 31, 2026
Industry median 10.44% (56 companies)
Return on Equity
5.50%
as of March 31, 2026
Industry median 10.16% (58 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

3 of 6 met
  • Yes Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (0.09)
  • No Return on equity is 15% or more (5.5%)
  • Yes Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

2 of 2 met
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

2 of 2 met
  • Yes Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

2 of 6 met
  • Yes Price sits in the Buy zone of its own historical PE range (Buy Zone)
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs SENSEX)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-0.1%
Low 64.3500 · High 75.0000
1W return
-3.5%
Low 64.3500 · High 75.0000
1M return
-15.2%
Low 64.3500 · High 82.0000
52W return
269.6%
Low 64.3500 · High 83.9900
Lifetime High ₹82.5000 (Aug. 31, 2026)
Lifetime Low ₹1.8500 (March 3, 2020)

Full price history and technicals →

EMA & SMA

Bullish3
Bearish3
5D
70.8
10D
72.5
20D
73.2
50D
62.9
100D
47.0
200D
23.6

Delivery and volume

Day avg. delivery
90.7%
Week avg. delivery
88.2%
Month avg. delivery
95.3%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

69.78
Pivot
First resistance75.22
Second resistance80.43
Third resistance85.87
First support64.57
Second support59.13
Third support53.92
Day RSI45.0
Day MFI49.6
Day MACD0.91
Day MACD signal3.03

Beta

1M-0.79
3M-0.21
1Y-0.21
3Y-0.12

Price change analysis

↓ -15.2%
Over 1 Month
LowHigh
64.3582.00
↑ 269.6%
Over 3 Months
LowHigh
64.3583.99
↑ 269.6%
Over 6 Months
LowHigh
64.3583.99
↑ 269.6%
Over 1 Year
LowHigh
64.3583.99
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 37.4 (own history: 10.1–99.7)
Buy Zone
Revenue (June 30, 2026)
₹37 Cr
Net profit (June 30, 2026)
₹— Cr
Basic EPS (June 30, 2026)
₹0.4900

Ranks #None of 62 in Healthcare Services by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter50.57%

Largest holders

Data unavailable.

Historical promoter holding

Promoters holdings increased from 49.43% to 50.57% in Jun 2026 qtr

All shareholding details →

DateClientDealActionQuantityPriceExchange
3 Jul 2025 MEDO CAPITAL SERVICES PRIVATE LIMITED Bulk Sell 125,000 43.2900 BSE
12 Jan 2022 BEKAE PROPERTIES PRIVATE LIMITED Bulk Sell 57,133 8.5500 BSE
12 Jan 2022 INDUS CAPITAL PRIVATE LIMITED Bulk Buy 57,133 8.5500 BSE
9 May 2014 KIRAN BHANGADIA Bulk Buy 43,000 7.1100 BSE
21 Feb 2014 ARUN KUMAR BHANGADIA Bulk Buy 50,000 4.6600 BSE
20 Feb 2014 ARUN KUMAR BHANGADIA Bulk Buy 60,000 4.6800 BSE
14 Feb 2014 SHREEVISHWAMURTE TRADINVEST PRIVATE LIMITED Bulk Buy 61,009 5.3800 BSE
7 Feb 2014 PREETI GAGAN ARORA Bulk Buy 71,453 6.2700 BSE
7 Feb 2014 PREETI GAGAN ARORA Bulk Sell 71,453 6.3800 BSE
31 Jan 2014 SHREEVISHWAMURTE TRADINVEST PRIVATE LIMITED Bulk Buy 66,448 7.3000 BSE

All bulk and block deals →

Corporate Actions

Full history (2 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
—NAME_CHANGEName changed from Trimurthi Drugs & Pharmaceuticals Limited to Trimurthi Limited
—NAME_CHANGEName changed from Trimurthi Limited to NOVELIX PHARMACEUTICALS LIMITED

All corporate actions →

Corporate Announcements

All 5 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
1 Oct 2026 AGM/EGM Novelix Pharmaceuticals Ltd - 536565 - Shareholders Meeting- Voting Results
1 Oct 2026 AGM/EGM Novelix Pharmaceuticals Ltd - 536565 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
30 Sep 2026 AGM/EGM Novelix Pharmaceuticals Ltd - 536565 - Shareholder Meeting / Postal Ballot-Outcome of AGM
30 Sep 2026 Insider Trading / SAST Novelix Pharmaceuticals Ltd - 536565 - Closure of Trading Window
9 Sep 2026 Company Update Novelix Pharmaceuticals Ltd - 536565 - Announcement under Regulation 30 (LODR)-Newspaper Publication

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.09)
  • Comfortable interest coverage (38.7x)
  • Healthy liquidity (Current Ratio 2.14)
  • Strong revenue growth YoY (65.2%)

Weaknesses

  • Low Return on Equity (5.5%)
  • Thin net profit margin (3.6%)

Opportunities

  • PEG below 1 (0.17) -- earnings growth outpacing its own valuation

Threats

  • PE above 35 (37.4) -- priced for continued strong execution

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about NOVELIX PHARMACEUTICALS LIMITED

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.